about
The Tobacco mosaic virus movement protein associates with but does not integrate into biological membranes.What is the future of pharmacogenomics in pain management?Pharmacogenomics in pain treatment.Erectile dysfunction in patients with chronic pain treated with opioids.The relationship of salivary testosterone and male sexual dysfunction in opioid-associated androgen deficiency (OPIAD).Causality assessment of liver injury after chronic oral amiodarone intake.Cost and effectiveness of lung lobectomy by video-assisted thoracic surgery for lung cancerPatellins 3 and 6, two members of the Plant Patellin family, interact with the movement protein of Alfalfa mosaic virus and interfere with viral movement.The movement protein (NSm) of Tomato spotted wilt virus is the avirulence determinant in the tomato Sw-5 gene-based resistance.The existence of a relationship between increased serum alanine aminotransferase levels detected in premarketing clinical trials and postmarketing published hepatotoxicity case reports.Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards.Hepatotoxicity related to paraquat and diquat absorption through intact skin.Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics.Opioids Increase Sexual Dysfunction in Patients With Non-Cancer Pain.Drug-drug interactions. Things to do in pain management.Real-world Data on the Efficacy of Vernakalant for Pharmacological Cardioversion in Patients With Recent-onset Atrial FibrillationSleep Problems in Adults With Autism Spectrum Disorder and Intellectual DisabilityPersonalized medicine into health national services: barriers and potentialities[Bioethics and the legal acting basis upon a Jehova's witness patient's who refuse to receive a blood transfusion]Citalopram-induced Raynaud's phenomenonA sibutramine-induced delusional disorder relapseKetanserin potentiates morphine-induced antinociception mediated by kappa-receptor activation[Conscientious objection within the public health system]β2‑adrenergic receptor functionality and genotype in two different models of chronic inflammatory disease: Liver cirrhosis and osteoarthritisOPRM1 influence on and effectiveness of an individualized treatment plan for prescription opioid use disorder patientsPharmacogenetics in Pain TreatmentAssociation of cannabinoid receptor genes (CNR1 and CNR2) polymorphisms and panic disorderPharmacogenetics and prediction of adverse events in prescription opioid use disorder patientsHealth benefits of an adverse events reporting system for chronic pain patients using long-term opioidsOPRM1 Gene Interaction with Sleep in Chronic Pain Patients Treated with OpioidsGender based differences, pharmacogenetics and adverse events in chronic pain managementGenetic Contribution in Low Back Pain: A Prospective Genetic Association StudySpanish list of potentially inappropriate drugs in the elderly (ES-PIA project)Evaluation of agomelatine for the treatment of sleep problems in adults with autism spectrum disorder and co-morbid intellectual disabilityRandomized, Controlled, Crossover Study of Self-administered Jacobson Relaxation in Chronic, Nonspecific, Low-back PainPersonality and psychiatric disorders in chronic pain male affected by erectile dysfunction: prospective and observational studyEffect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects
P50
Q38329520-D6490F7F-896B-4CBA-BDB8-29732DC9135CQ38780828-80BB6A6D-D3E2-4ED8-B2F3-AADF6D8E321BQ38818279-10E2DD90-0B82-4B5A-A0FB-1266ED97AFE6Q38942786-CECF6C5F-F37C-41C1-8BE0-3259913BF241Q39280821-658270B8-76E4-40EC-B890-ECC418F3F474Q40007955-6BCD8A47-DA08-478E-8195-9991A543E798Q41301590-FFACB858-1932-4CB5-99B9-66B7DCF5ABDAQ42223277-926E8282-DE78-4A9F-9C15-886262FDA83CQ42227628-D46451D3-F214-4691-A9FF-32991C0966FFQ43120937-F592C36D-9D0E-45D3-B6AB-FC20717D92C6Q46257861-B9814BE0-FEA3-4460-926F-4C963DBD4EC3Q46971415-A2EB2C9B-5725-415D-A822-80452EC95A7AQ46985552-28A1CDF4-3C30-498E-94BE-12812816E0BCQ47398797-718DF0AF-B9F4-4ACB-9A90-7A174D9A0660Q50157036-32850375-5646-413C-8BDC-42AE1206CE22Q56893666-A7395B14-BB8E-4E99-9D22-2A9E3DCFD935Q57052443-4C5255DF-9544-4A99-8E12-72D813E086FBQ58613949-21EC6B75-8A2C-45AC-A423-D2335030BAA3Q58671615-D079E49B-5DDF-43CE-949F-EFD7375A9D0CQ79356362-491B0B57-CD6B-42A7-A201-58DF406EE349Q79794394-F718259C-43D4-40C9-87DE-602139DF23D3Q83656323-C1614EFE-577B-4489-8382-27D56BC74D24Q84088074-6653AFCB-2854-4A71-AE3A-B0036D017784Q88274076-EF2C7640-F32E-4CCE-9020-BBCF46A9E9F2Q88749294-5C834681-D1BB-4AE1-A741-61E5DBB709A4Q88818038-3AA7433E-D1AB-4737-BBB8-68B7F6EE5B55Q89958393-C241507F-1BDC-4F2C-B393-37305C7BF1A1Q90483954-B9BEF805-91BA-45FD-A9D0-A5FB0C195D61Q90954757-B3C3FAD3-5B73-4C23-B0C2-C3ED54A9CCADQ91281471-1A458818-1E32-4026-8AAC-C109A6046964Q91345031-F44C6D62-39B2-4E40-9DDA-D93BD4C2D44EQ91585400-81E754A4-F123-4D1D-92E5-739E509C2BC2Q91839231-37C0F658-544D-4645-8FC5-F26C0AED0D6BQ92688971-5843D856-461D-4814-8C77-812F8B40E245Q93077178-E4716E6B-8BEB-45D2-B5F9-B94291DA28C4Q94550836-277307DE-F870-4D2F-A824-35F488C7837AQ94949103-CE78175F-D410-4AE4-9761-407358DA54F6
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
A M Peiró
@en
A M Peiró
@nl
type
label
A M Peiró
@en
A M Peiró
@nl
prefLabel
A M Peiró
@en
A M Peiró
@nl
P31
P496
0000-0002-2385-3749